Cellectar Biosciences, Inc.CLRBNASDAQ
Loading
Asset Growth Under PressureDecelerating
Percentile Rank69
3Y CAGR-41.1%
5Y CAGR-58.0%
Year-over-Year Change
Year-over-year total asset growth rate
3Y CAGR
-41.1%/yr
Quarterly compound
5Y CAGR
-58.0%/yr
Recent acceleration
Percentile
P69
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 2.40% |
| Q3 2025 | 6.81% |
| Q2 2025 | -14.63% |
| Q1 2025 | -37.03% |
| Q4 2024 | -31.69% |
| Q3 2024 | 26.91% |
| Q2 2024 | -31.52% |
| Q1 2024 | 255.33% |
| Q4 2023 | -43.97% |
| Q3 2023 | 231.08% |
| Q2 2023 | -56.13% |
| Q1 2023 | -31.27% |
| Q4 2022 | 11.75% |
| Q3 2022 | -25.39% |
| Q2 2022 | -19.06% |
| Q1 2022 | -14.01% |
| Q4 2021 | -11.33% |
| Q3 2021 | -12.12% |
| Q2 2021 | -13.31% |
| Q1 2021 | -6.13% |
| Q4 2020 | 183.42% |
| Q3 2020 | -13.23% |
| Q2 2020 | 174.50% |
| Q1 2020 | -29.07% |
| Q4 2019 | -21.77% |
| Q3 2019 | -18.17% |
| Q2 2019 | 52.49% |
| Q1 2019 | -16.64% |
| Q4 2018 | -22.96% |
| Q3 2018 | 179.28% |
| Q2 2018 | -26.82% |
| Q1 2018 | -25.72% |
| Q4 2017 | 30.39% |
| Q3 2017 | -21.66% |
| Q2 2017 | -17.62% |
| Q1 2017 | -0.18% |
| Q4 2016 | 64.85% |
| Q3 2016 | -18.30% |
| Q2 2016 | 104.28% |
| Q1 2016 | -26.68% |